Boston Scientific (NYSE: BSX) director Ellen M. Zane receives $215,000 stock grant

Rhea-AI Filing Summary

Zane Ellen M reported acquisition or exercise transactions in this Form 4 filing.

BOSTON SCIENTIFIC CORP director Ellen M. Zane received an annual equity award of common stock. She was granted 3,800 shares of restricted stock on May 7, 2026 at no cash cost per share. The award reflects a value of $215,000 divided by the closing price of the common stock on the grant date and will vest in full at the next annual meeting of stockholders. After this grant, she directly holds 27,934 common shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Zane Ellen M

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	3,800	$0.00	--

Holdings After Transaction: Common Stock — 27,934 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Restricted stock grant: 3,800 shares Award value: $215,000 Price per share in grant: $0.0000/share +3 more

6 metrics

Restricted stock grant 3,800 shares Annual equity award granted on May 7, 2026

Award value $215,000 Value divided by closing price on grant date

Price per share in grant $0.0000/share Non-cash equity compensation grant

Shares owned after grant 27,934 shares Total direct common stock holdings after transaction

Transaction code A (Grant, award, or other acquisition) Non-derivative common stock transaction

Transaction direction acquire Grant/award acquisition of common stock

Key Terms

restricted stock, annual equity award, closing price, Form 4

4 terms

restricted stock financial

"Annual equity award in the form of restricted stock vesting in full upon the next annual meeting"

Shares granted to an individual that carry limits on transfer or sale until certain conditions are met, such as staying with the company for a set time or hitting performance targets. Think of them as a locked gift that gradually opens; for investors they matter because they affect how many shares may enter the market later, signal management incentives and potential dilution, and reveal confidence in future company performance.

annual equity award financial

"Annual equity award in the form of restricted stock vesting in full upon the next annual meeting"

closing price financial

"Reflects a value of $215,000 divided by the closing price of common stock on the date of grant"

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Zane Ellen M

(Last) (First) (Middle)

300 BOSTON SCIENTIFIC WAY

(Street)

MARLBOROUGH MASSACHUSETTS 01752-1234

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BOSTON SCIENTIFIC CORP [ BSX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/07/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/07/2026		A(1)		3,800	A	$0.0000	27,934	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $215,000 divided by the closing price of common stock on the date of grant.

	/s/ Susan Thompson, Attorney-in-Fact	05/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Boston Scientific (BSX) director Ellen M. Zane report in this Form 4?

Ellen M. Zane reported receiving an annual equity award of 3,800 shares of Boston Scientific common stock. These are restricted shares granted as compensation, not an open-market purchase, and increase her direct holdings to 27,934 shares after the transaction.

How large is Ellen M. Zane’s new stock grant from Boston Scientific (BSX)?

The grant totals 3,800 restricted shares of Boston Scientific common stock. According to the footnote, it reflects a value of $215,000, calculated by dividing that amount by the stock’s closing price on the grant date.

When do Ellen M. Zane’s new Boston Scientific (BSX) restricted shares vest?

The 3,800 restricted shares vest in full upon the next annual meeting of stockholders. Until that vesting date, the award remains restricted stock tied to her service as a director on Boston Scientific’s board.

What is Ellen M. Zane’s Boston Scientific (BSX) ownership after this Form 4 transaction?

After the reported equity award, Ellen M. Zane directly owns 27,934 shares of Boston Scientific common stock. This total includes the newly granted 3,800 restricted shares reported in the Form 4 filing.

Was cash paid for Ellen M. Zane’s Boston Scientific (BSX) stock award?

No cash changed hands for this award; the reported price per share is $0.0000. It is a non-cash equity compensation grant of restricted stock rather than an open-market purchase or sale.